73 results
Page 2 of 4
8-K
EX-99.1
ffws34 mg0qsk9i91n
12 May 22
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:21pm
424B5
g0k20jl0jy 73
24 Mar 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
vkffd
26 Jan 22
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
8:15am
424B5
r0xviny702ig9
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
n7of b8j1jp
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
8-K
EX-99.1
mk8 9w2xet5oi
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
38iou4x7ojs9 06jx
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
ro445
12 Apr 21
Prospectus supplement
1:44pm
S-3
z3lilt 821kdksxz87
2 Apr 21
Shelf registration
12:00am
8-K
EX-99.1
etqswioqfn6szej25
25 Mar 21
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
12:00am
8-K
EX-99.1
aokrgnm jb6jx
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
zl4vro
11 Jan 21
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
1:35pm